Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB3 pilot study in delayed graft function after DCD kidney transplantation
NL-OMON32550Phase 2Withdrawn
- Sponsor
- Angion Biomedica Corp.
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of terevalefim in delayed graft function (DGF), acute kidney failure (AKF), sponsored by Angion Biomedica Corp.. Planned start Oct 2009; status: withdrawn.
02
Drugs
terevalefim
03
Conditions
delayed graft function (DGF)acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON32550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32550.